Efficacy and Safety of Infliximab Biosimilar in Treatment of Resistant Hidradenitis Suppurativa

Sex: All

Ages: 18 Years – 60 Years

Phase: EARLY_PHASE1

Enrollment: 16

Sponsor: Services Institute of Medical Sciences, Pakistan

Summary

The aim of this clinical trial is to assess the efficacy and safety of Infliximab biosimilar in patients of resistant Hidradenitis suppurativa. The main question it aims to answer are:how effective is infliximab biosimilar in treating resistant Hidradentis suppurativaIs infliximab biosimilar safe in these patients Patients will receive weekly injections of Infliximab Biosimilar Remsima, according to weight, for first 4 weeks, and then fortnightly for next 10 weeks. Patients will be followed up for 10 weeks post treatment for assessment of safety and efficacy

Eligibility Criteria

Inclusion Criteria:Patients of Hidradenitis suppurativa resistant to conventional therapyExclusion Criteria:Immunocompromised patientsPatients with connective tissue disorderspatients having chronic infections like heapatitis, HIV or TuberculosisPregnant or lactating mothers

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT05663268). StuddyBuddy aggregates publicly available trial information.